Caption Management’s CytomX Therapeutics CTMX Stock Holding History

Caption Management’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.63M	Sell	700,000 -200,000	-22%	-$764K	0.01%	815
2026 Q1	$4.23M	Buy	+900,000	New	+$4.57M	0.02%	583
2025 Q4	–	Sell	-249,900	Closed	-$797K	–	1658
2025 Q3	$797K	Buy	249,900 +174,900	+233%	+$394K	0.01%	1182
2025 Q2	$170K	Buy	+75,000	New	+$121K	﹤0.01%	1277

Other funds holding CTMX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Caption Management's CTMX Position: Q2 2026 in Review

Caption Management reduced its CytomX Therapeutics (CTMX) stake by 48% in Q2 2026, selling an estimated $1.04M and leaving 300,000 shares worth $1.13M. The position accounts for 0.01% of the portfolio, ranked #1094.

Caption Management first reported a position in CTMX in Q1 2026 and has held it in 2 quarters since. The position peaked at $2.69M in Q1 2026. 178 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

Caption Management held 300,000 shares of CytomX Therapeutics worth $1.13M as of Q2 2026.
Caption Management sold 273,224 CytomX Therapeutics shares in Q2 2026, an estimated $1.04M.
CytomX Therapeutics made up 0.01% of Caption Management's portfolio in Q2 2026, its #1094 holding.
Caption Management first reported a position in CytomX Therapeutics in Q1 2026 and has held it in 2 quarters since.
Caption Management's CytomX Therapeutics position peaked at $2.69M in Q1 2026.
178 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Caption Management's 13F filing for Q2 2026, filed 14 Aug 2026.